Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Phase 3

Active, not recruiting

Conditions: Stage I Lung Cancer AJCC v8
Stage II Lung Cancer AJCC v8
Stage III Lung Cancer AJCC v8
Limited Stage Lung Small Cell Carcinoma

Interventions: Radiation: 3-Dimensional Conformal Radiation Therapy
Procedure: Biospecimen Collection
Drug: Atezolizumab
Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Radiation: Intensity-Modulated Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2019-01-22

Last Posted Date: 2024-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 545

Registration Number: NCT03811002

Locations: 🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Fairbanks Memorial Hospital, Fairbanks, Alaska, United States

and more 542 locations

Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Quizartinib
Drug: Fludarabine
Drug: Cytarabine
Drug: Intrathecal (IT) triple chemotherapy prophylaxis
Drug: Etoposide

First Posted Date: 2019-01-04

Last Posted Date: 2024-11-07

Lead Sponsor: Daiichi Sankyo

Target Recruit Count: 65

Registration Number: NCT03793478

Locations: 🇺🇸
Loma Linda University Cancer Center, Loma Linda, California, United States
🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States

and more 25 locations

BuCE Versus BuME as Conditioning Therapy in Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Non-hodgkin Lymphoma

Interventions: Drug: Busulfan
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan

First Posted Date: 2019-01-04

Last Posted Date: 2019-01-07

Lead Sponsor: Soonchunhyang University Hospital

Target Recruit Count: 75

Registration Number: NCT03794167

Locations: 🇰🇷
Jong-Ho Won, Seoul, Korea, Republic of

Busulfan, Melphalan and Etoposide as Conditioning for Autologous Transplantation for Non-Hodgkin's Lymphoma (NHL)

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma

Interventions: Drug: Busulfan
Drug: Melphalan
Drug: Etoposide

First Posted Date: 2019-01-03

Last Posted Date: 2019-01-04

Lead Sponsor: Soonchunhyang University Hospital

Target Recruit Count: 51

Registration Number: NCT03792815

Locations: 🇰🇷
Soonchunhyang University Hospital, Seoul, Korea, Republic of

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Phase 2

Active, not recruiting

Conditions: Ganglioneuroblastoma
High Risk Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carboplatin
Drug: Cisplatin
Drug: Cyclophosphamide
Drug: Dexrazoxane
Biological: Dinutuximab
Drug: Doxorubicin
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Drug: Isotretinoin
Drug: Melphalan
Biological: Sargramostim
Drug: Thiotepa
Drug: Topotecan
Drug: Vincristine

First Posted Date: 2018-12-26

Last Posted Date: 2024-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT03786783

Locations: 🇺🇸
Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
🇳🇿
Starship Children's Hospital, Grafton, Auckland, New Zealand
🇦🇺
The Children's Hospital at Westmead, Westmead, New South Wales, Australia

and more 7 locations

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: bendamustine
Drug: Etoposide
Drug: Doxorubicin
Drug: Bleomycin
Drug: Vincristine
Drug: Brentuximab Vedotin
Drug: Vinblastine
Drug: Cyclophosphamide
Drug: Prednisone
Drug: DTIC
Drug: Filgrastim
Other: Quality of Life Measurements
Radiation: Radiotherapy

First Posted Date: 2018-11-28

Last Posted Date: 2024-04-04

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 250

Registration Number: NCT03755804

Locations: 🇺🇸
Maine Children's Cancer Program, Scarborough, Maine, United States
🇺🇸
St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge, Louisiana, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 5 locations